SCHEMBL4050330

SCHEMBL4050330

Fc1ccccc1-c1n[c]ccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.36
NISCH Q9Y2I1 1/20 0.36
KDM4E B2RXH2 3/20 0.35
RAB9A P51151 3/20 0.35
PKM P14618 2/20 0.35
KMT2A Q03164 2/20 0.35
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ALDH1A1 P00352 2/20 0.33
NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4973490 0.78 ALDH1A1 (0.43) NPC1KDM4ERAB9AKMT2AL3MBTL1
SCHEMBL31517695 0.78 NPC1 (0.46) NPC1NISCHKDM4ERAB9APKM
SCHEMBL4400229 0.78 NPC1 (0.46) NPC1NISCHKDM4ERAB9APKM
SCHEMBL468098 0.72 NPC1 (0.42) NPC1RAB9AKMT2AL3MBTL1SMN1; SMN2
SCHEMBL4695390 0.72
SCHEMBL184122 0.71 CYP2A6 (0.30)
SCHEMBL1202032 0.69 IDO1 (0.43) NPC1NISCHKDM4ERAB9APKM
SCHEMBL4044285 0.69 MEN1 (0.43) NPC1RAB9AKMT2AHDAC1HDAC6
SCHEMBL9341878 0.69 KDM4E (0.54) NPC1KDM4ERAB9APKML3MBTL1
SCHEMBL28296096 0.69 NPC1 (0.50) NPC1KDM4ERAB9APKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107709334-A New amino acid derivativges, its preparation method and include their Pharmaceutical composition 法国施维雅药厂 2018-02-16 CN disclosed
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed
EP-0513656-A1 Process for dyeing of silanes modified with fibermaterials, the modification of fibermaterials with silanes HOECHST AKTIENGESELLSCHAFT (DE) 1992-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R NPC1 4195/4885NISCH 1902/4885KDM4E 2034/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R NPC1 4203/4885NISCH 1980/4885KDM4E 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.